Skip to content
  1. Home
  2. Sexual health
  3. PT-141 (Bremelanotide)

Sexual health

PT-141 (Bremelanotide)

A melanocortin-receptor agonist that acts on the brain's sexual-arousal pathways rather than on blood flow directly — FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, used off-label by men for erectile/libido support.

FDA-approved (women's HSDD) Sexual health

Reviewed 2026-09-12
Full name
Bremelanotide
Also known as
PT-141, Vyleesi (FDA-approved brand, for women)
Regulatory status
FDA-approved prescription drug (Vyleesi) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Used off-label, including by men, and also available through the grey/research-chemical market outside a prescription.
Variant note
Occasionally discussed alongside PSK/other melanocortin-pathway variants sold under adjacent names; PT-141 (bremelanotide) itself is the only form with FDA approval (as Vyleesi, for HSDD in women) and the only form with real human trial data.

Origin

A synthetic analog of alpha-MSH engineered specifically for activity at melanocortin 4 receptors (MC4R) in the brain, which govern sexual arousal, distinct from the pigmentation-related MC1R pathway.

Mechanism

Unlike PDE5 inhibitors (sildenafil, tadalafil), which work locally by increasing blood flow to genital tissue, bremelanotide acts centrally on melanocortin receptors in the neural arousal pathway. That's why it's framed as addressing 'desire' rather than mechanical erectile function, and why it treats a condition, HSDD, that PDE5 inhibitors don't touch.

Research summary

Evidence

The RECONNECT trials that supported Vyleesi's FDA approval were conducted in premenopausal women with HSDD and showed statistically significant improvement in desire and reduction in distress versus placebo, though the effect size was modest and placebo response was meaningful too, typical for this trial category. Male sexual-function research on bremelanotide is smaller in scale, mostly from earlier-stage development, including erectile dysfunction trials before development pivoted to the female HSDD indication. It showed improved erectile response, but that's not the compound's approved use in men.

Evidence tier: FDA-approved (women's HSDD) — see the methodology note for how this is assessed.

Citations

Reported benefits

  • Increased subjective sexual desire/arousal, the primary effect in its approved female indication
  • Reported improved erectile response in men (off-label use), sometimes combined with PDE5 inhibitors for complementary mechanisms
  • Effect is described by users as psychological/arousal-focused rather than purely mechanical

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Subcutaneous injection (approved autoinjector dose)The approved Vyleesi dose is 1.75 mg, self-injected at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than 8 doses per month.
Off-label / self-sourced use (commonly lower doses than the approved autoinjector)Community-reported doses are often lower than the approved 1.75 mg autoinjector dose, commonly in the 0.5-1.5 mg range, adjusted based on side-effect tolerance (particularly nausea), taken roughly an hour before activity.

Side effects

  • Nausea is the most common and often dose-limiting side effect — frequently reported and can be significant
  • Flushing, headache
  • Transient increase in blood pressure and decrease in heart rate observed in trials — worth caution for anyone with cardiovascular disease
  • Skin/gum darkening has been reported with frequent, prolonged use, related to melanocortin receptor activity on pigmentation pathways

Safety notes

Safety: Nausea is common enough that many users experiment with the lowest effective dose instead of the full approved autoinjector amount. Blood pressure and heart rate effects warrant caution for anyone with cardiovascular conditions, and should be discussed with a physician even for off-label male use.
Community & reddit notes (anecdotal — not clinical evidence)

Widely discussed as an alternative or complement to PDE5 inhibitors, specifically because it works on desire and arousal rather than blood flow. Some men report using both together for a more complete effect. Nausea management, via lower doses or timing around meals, is the most common practical topic in user communities.

Mixing compatibility

Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.

Used together in wellness-clinic protocols

Reported as a combination to avoid